Neurophet Participates ASNR 2025: Showcasing Clinical Utility of 'Neurophet AQUA AD'
Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA AD Company accelerates partnerships with global pharmaceutical companies and neurology KOLs to drive...
Neurophet to Participate in RSNA 2024: Unveiling Multiple Sclerosis Analysis Technology with Neurophet AQUA
Demonstrates MS Analysis Technology, Recently Secured FDA 510(k) Clearance Introduces 'Neurophet AQUA AD,' a Total Solution for Alzheimer's Disease Treatment Prescription, at the AI Theater SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- Neurophet,...
Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with 'Neurophet AQUA'
New features include advanced analysis of multiple sclerosis (MS) and white matter hyperintensities alongside brain atrophy analysis Accelerating global expansion with cutting-edge technology targeting MS, a prevalent condition in North America and...